They work inside integrated development environments (IDEs), where code, documentation, testing, version history and ...

Achieve Life Sciences is a single-asset microcap centered on cytisinicline, with an accepted NDA and a June 20, 2026, PDUFA.

As the life sciences and Medtech sectors undergo rapid transformation, new priorities are reshaping where companies choose to grow. A new report from the Hickey Institute explores the evolving ...

It's the final day to submit your nominees for this year's Fiercest Women in Life Sciences! The nomination form will close at 11:59 p.m. ET on Friday, Sept. 26. Every year, we celebrate women making a ...

Research shows that women remain woefully underrepresented at the highest levels of leadership in the life sciences industry. Those who have broken through that glass ceiling, however, are not only ...

T he U.S. life sciences real estate market posted positive net absorption in the fourth quarter even as robust construction completions raised the sector’s vacancy rate to 19.7%, according CBRE’s new ...

Anthropic is launching Claude for Life Sciences, a new model aimed at aiding scientific research. Through integrations with leading life sciences players, the platform will help researchers at every ...

Caris Life Sciences has collected $168 million in new funding to support the growth of its precision medicine platforms, following the FDA’s approval of its multi-cancer companion diagnostic test last ...

Is Back On Investors’ Radar Veeva Systems (VEEV) is drawing fresh attention after a sharp pullback in information technology stocks tied to fears of artificial intelligence disruption, even as new ...

William “Bill” McKeon is the President and Chief Executive Officer of the Texas Medical Center. He is responsible for driving strategic, operational and programmatic initiatives across the Texas ...

LIR Life Sciences is a leader in the dvancement of novel, needle-free drug delivery platforms for obesity treatment across ...

Ed Field is President of BioLabs NC. Mr. Field has 20+ years c-level experience in building and selling numerous early-stage and publicly-traded biotechnology companies. He has been responsible for ...